On March 28, 2018 Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, reported that Company Management will be presenting at two upcoming healthcare investor conferences (Press release, Histogenics, MAR 28, 2018, View Source;p=RssLanding&cat=news&id=2340115 [SID1234525026]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright Global Life Sciences Conference – Monte Carlo, Monaco (April 8-10, 2018)

Jonathan Lieber, Histogenics’ CFO, will present a corporate overview on Tuesday, April 10, 2018 at 11:55a.m. CEST / 5:55 a.m. EDT.
Alliance for Regenerative Medicine 6th Annual Cell and Gene Investor Day – New York, NY (April 17, 2018)

Sponsored by the Alliance for Regenerative Medicine, the conference provides institutional, strategic and venture investors a unique opportunity to gain insight into over 30 leading cell and gene therapy companies. Mr. Lieber will present a corporate overview on Tuesday, April 17, 2018 at 9:10 a.m. EDT.
To access live audio webcasts of the presentations on the "Investor Relations" page of the Histogenics website, please click here. The webcasts will be available for approximately 45 days following the respective conferences.